

1 **Early Experience with Ivabradine for Focal Atrial Tachycardia in**
2 **Pediatric Patients with Congenital Heart Disease**

3 Drishti Tolani¹ MBBS, Nawin L. Ramdat Misier^{1,2} BSc, Manal Alqahtani¹ MBBS, Kaitlin Tindel³
4 PharmD, William A. Scott¹ MD, Hoang H. Nguyen^{1,2} MD

5

6 ¹Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA

7 ²Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands

8 ³Department of Pharmacy, Dallas Children’s Medical Center, Dallas, Texas, USA

9

10

11 Short title: Ivabradine for AT in CHD pediatrics

12 Word count: 3201

13 Disclosures: None

14

15 *Correspondence to:*

16 Hoang H. Nguyen MD

17 The University of Texas Medical Center

18 5323 Harry Hines Boulevard

19 Dallas, TX 75235

20 E-mail: hoang.nguyen@utsouthwestern.edu

21 **Abstract**

22 Background: Ivabradine is a promising anti-arrhythmic therapy for automatic arrhythmias
23 such as inappropriate sinus tachycardia, junctional ectopic tachycardia, and focal atrial
24 tachycardia (AT). However, experience with ivabradine in pediatric patients, especially those
25 with congenital heart disease (CHD) and focal AT, remains limited. We report our findings
26 using ivabradine for focal AT in infants and children with CHD to assess its efficacy and
27 safety.

28 Method: A retrospective analysis was conducted on all pediatric patients (<21 years)
29 diagnosed with CHD at Children's Health of Dallas, who were treated with ivabradine for
30 focal AT. Patient demographics, arrhythmia diagnosis, anti-arrhythmic therapies, and
31 adverse effects were evaluated. A positive response was defined as complete rhythm control
32 within 24 hours of initiation of ivabradine.

33 Results: Fifteen patients (median age 7 [1-8] months; 9 males (60%)) were included in this
34 study, including 12 (80%) complex CHD. Fourteen patients (93%) had unifocal AT and one
35 (7%) had multifocal AT. The AT occurred in the early post-operative period in six patients
36 (40%). In two patients (13%) ivabradine was used as monotherapy. Positive response to
37 ivabradine was observed in 12 patients (80%). Adverse events occurred in 7 patients (47%)
38 consisting of bradycardic, which was transient, or resolved upon reducing the ivabradine
39 dosage.

40 Conclusion: In infants and children with CHD, ivabradine was efficacious for the treatment of
41 focal AT without major complications. Bradycardia is a frequent adverse event. Therefore,
42 close monitoring may be required during initiation of therapy.

43 Key words: pediatric, atrial tachycardia, congenital heart disease, anti-arrhythmic agent

44 **Abbreviations**

45 AT= atrial tachycardia

46 CHD= congenital heart disease

47 JET= junctional ectopic tachycardia

48 **Introduction**

49 Ivabradine is an anti-arrhythmic agent that reduces the heart rate by inhibiting the
50 pacemaker current, which is responsible for spontaneous depolarization of the sinoatrial
51 node.(1) Currently, ivabradine is primarily used for treatment of inappropriate sinus
52 tachycardia and sinus tachycardia related to heart failure, in adults.(2, 3) More recently,
53 there has been increasing experience with ivabradine for junctional ectopic tachycardia (JET)
54 in pediatric patients.(4) As abnormal spontaneous diastolic depolarization is the
55 pathophysiologic mechanism for focal atrial tachycardia (AT), i ivabradine may be an
56 effective therapy.(5)

57 Experience with ivabradine in pediatric patients with focal AT is limited to small case series,
58 often lacking patients with congenital heart disease (CHD).(6-11) In young patients with CHD,
59 AT is a significant source of morbidity and mortality.(12, 13) Multiple anti-arrhythmia agents
60 are moderately effective in treating AT; however, all have potentially significant side effects,
61 which could outweigh their benefits.(12-14) An important advantage of ivabradine is its high
62 selectivity. It does not have negative inotropic effects or prolong repolarization.(1, 4, 15)

63 We, therefore, report in this single-center study our early experience using ivabradine for
64 focal AT in infants and children with CHD to assess its efficacy and safety.

65 **Methods**

66 A retrospective review was conducted on all pediatric patients at Children's Health of Dallas
67 who were treated with ivabradine for focal AT. The inclusion criteria for the study were
68 pediatric patients <18 years with CHD and focal AT, who were treated with ivabradine as
69 inpatients.

70 Our center has been using ivabradine for AT since August 2020, and all retrospective data
71 available from August 2020 until May 2023 were collected. Local institutional review board
72 approval was obtained, and informed consent was waived.

73 ***Ivabradine protocol***

74 Data were retrieved from medical records and included demographic characteristics, type of
75 CHD, date and types of cardiac procedures, comorbidities, pharmacological therapy before
76 ivabradine treatment, electrocardiographic recordings, and echocardiographic recordings.

77 Analysis of inpatient telemetry, standard 12 lead electrocardiogram and atrial wire studies
78 were utilized for diagnosis. Focal AT was confirmed by a pediatric electrophysiologist.
79 Incessant focal AT was defined as a continuous tachycardia without spontaneous
80 termination or continuous paroxysms of tachycardia separated by ≤ 2 sinus beats and lasting
81 >24 hours.

82 Pediatric patients were treated with ivabradine when able to receive PO medication.
83 Decision to initiate ivabradine was left to the treating electrophysiologist in consultation
84 with the primary care team. In general, first-line treatment with ivabradine was considered
85 when the AT was not critical. Ivabradine was also used as second or third-line agent to
86 supplement or replace medications that were not completely effective. Generally,

87 ivabradine was administered at an initial dose of 0.05 mg/kg (a dosage of 2.5 mg for patients
88 weighing ≥ 30 kg) every 12 hours under continuous telemetry of ECG and oxygen
89 saturation. Blood pressure was monitored by indwelling line or frequent noninvasive
90 measurements. Treatment was considered successful if rhythm control was achieved within
91 24 hours of ivabradine initiation. The dosage of ivabradine was increased to 0.1 mg/kg, when
92 the first dose showed no effect on the heart rhythm or rate. If ivabradine was not successful
93 within 24 hours, it was discontinued. In patients for whom first-line ivabradine was
94 ineffective, other antiarrhythmic drugs were prescribed. In cases of successful ivabradine
95 therapy, ongoing discussion with the primary care team determined the duration of therapy.
96 Ivabradine dosage was lowered for clinically relevant bradycardia. Side effects, including
97 acute hemodynamic changes, bradycardia and pro-arrhythmia, were specifically sought out.

98 ***Statistical analysis***

99 Continuous data were described as medians [ranges] and categorical variables were
100 described as counts and percentages. Estimated statistics were performed for statistical
101 comparison.(16)

102 **Results**

103 *Study population*

104 Fifteen patients (9 males (60%)) were included in this study. The median age at ivabradine
105 initiation was 7 [1-8] months, with 6 patients (40%) being younger than 3 months old. Of the
106 12 the patients with complex CHD, 8 patients had single ventricle physiology and six patients
107 had heterotaxy syndrome. Four patients (27%) had diminished systolic ventricular function.
108 Baseline characteristics of the study are summarized in **Table 1**.

109 Fourteen patients (93%) had unifocal ectopy AT and one patient (7%) had multifocal AT. In
110 total, six patients (40%) developed AT early after cardiac surgery or interventional
111 catheterization. Six out of 15 ATs were incessant. None of the patients had prior atrial or
112 ventricular arrhythmias.

113 *Ivabradine regimen*

114 Ivabradine was used as first-line therapy in 4 patients (27%), second-line therapy in 6 (40%)
115 and third line in 1 (7%) (**Table 1**). In 4 additional patients (27%), ivabradine was
116 administered to avoid breakthrough of ATs. In total, 13 patients (87%) used ivabradine in
117 combination with other anti-arrhythmic medications, while only a minority (13%) used it as
118 monotherapy. Ten patients (67%) were on a combination of ivabradine and one other anti-
119 arrhythmic agent, including beta-blocker (N=2), flecainide (N=2), dexmedetomidine (N=2),
120 amiodarone (N=2) and digoxin (N=2). Three patients (20%) were on a combination with ≥ 2
121 anti-arrhythmic drugs: ivabradine with flecainide and amiodarone; ivabradine with a beta-
122 blocker and amiodarone; or ivabradine with a beta-blocker, flecainide, and digoxin.

123 The initial ivabradine dosage was 0.05 [0.05-0.05; min 0.02 – max 0.1) mg/kg. Two patients
124 received adult dosing at 2.5 mg (34 kg) and 5 mg (70 kg), resulting in 0.07 mg/kg in both
125 respectively. The maximum dosage during treatment was 0.07 [0.05-0.1; min 0.038-max
126 0.157) mg/kg, which was higher than the initial dose in 7 patients (all <1 year of age).

127 *Efficacy outcomes*

128 Positive response to ivabradine was observed in 12 patients (80%). During their in-hospital
129 stay, they were treated with ivabradine for a median duration of 6 [5-26] days, and none had
130 recurrence while on ivabradine therapy. In 3 patients (20%), all with post-operative AT,
131 ivabradine was unsuccessful in providing adequate rhythm control. The first patient had
132 incessant AT which did not respond to ivabradine despite optimization of the dose. After
133 discontinuation of ivabradine, rhythm control was achieved with after initiation of multiple
134 other anti-arrhythmic agents. The second patient continued to have multifocal AT on
135 ivabradine, although a more organized rhythm was observed. The third patient remained to
136 have breakthrough focal AT on ivabradine. After addition of flecainide, the patient was free
137 of AT.

138 After discharge, 3 of the 12 responders (25%) no longer required treatment. Two patients
139 (13%) had mono-drug therapy with ivabradine after discharge. The first patient was initially
140 weaned off ivabradine after discharge, but had recurrent AT 1 year after discharge, which
141 responded to ivabradine. The second patient received maintenance therapy with ivabradine,
142 without recurrence during follow-up. The 7 other patients (58%) either continued using one
143 or multiple other antiarrhythmic drugs, without ivabradine.

144 *Safety outcomes*

145 In total, 7 patients experienced adverse events (47%), all consisting of bradycardia alone.
146 Bradycardia occurred at a median of 3 [IQR 1-3] days after initiation of ivabradine, with a
147 maximum of 7 days. Five patients had sinus bradycardia, and 2 had functional bradycardia
148 due to blocked premature atrial contractions (PACs). All patients with bradycardia were
149 receiving concomitant anti-arrhythmic agents. Using estimated statistics, the unpaired
150 median differences in age between patients with and without bradycardia was -3.5 [95.0%CI
151 -85.0, 7.5] months (two-sided permutation t-test P value = 0.492).

152 In 4 patients, either a single dose was skipped or the chronic dose was halved, which
153 successfully restored sinus rhythm within 12 hours. In 1 patient, ivabradine was discontinued
154 due to bradycardia after conversion to sinus rhythm, after which patient had recurrence of
155 AT. Flecainide and propranolol successfully terminated the AT, but the AT recurred once
156 these medications were discontinued. Subsequently, ivabradine was initiated again and
157 successfully converted the AT to sinus rhythm without AT or bradycardia recurrence. In
158 another patient ivabradine was replaced by flecainide which resolved the functional
159 bradycardia. In the remaining 2 patients ivabradine regimen was not changed during well
160 tolerated bradycardia that spontaneously resolved later the same day.

161 **Discussion**

162 *Key findings*

163 In this retrospective single center study, we assessed for the first time the efficacy and safety
164 of ivabradine for focal AT in infants and children with CHD. The 80% response rate was high,
165 although often in combination with other anti-arrhythmic agents. Adverse events were
166 limited to bradycardia without significant clinical consequences.

167 *Clinical experience with ivabradine*

168 In recent years, additional indications for ivabradine have been explored, particularly in
169 pediatric patients, due to the favorable side effect profile.(4, 6, 15) In these young patients,
170 Ivabradine has recently been shown to be a promising pharmacological agent in the
171 treatment of heart failure and JET.(15) Similar to the adult population, there has also been
172 increasing interest in its use for automatic AT. However, the experience was limited to
173 several case-reports and small series in pediatrics, often with normal cardiac anatomy.(6-10)
174 Recently, Xu et al reported its single center experience with ivabradine monotherapy in 12
175 pediatric patients with focal AT and no CHD, who were resistant to conventional anti-
176 arrhythmic agents.(6) Ivabradine was effective in 50% of the patients, and well tolerated
177 without any events of bradycardia. However, except for a case-report, outcomes of
178 ivabradine in pediatric with congenital heart disease were unknown.(9)

179 Focal AT are not uncommon in pediatric patients with congenital heart disease, especially in
180 the early post-operative period.(14) In these patients, AT is often associated with
181 hemodynamic compromise and a three times higher mortality rate.(13) Not only are the current
182 anti-arrhythmogenic agents characterized by suboptimal efficacy, they also have negative
183 inotropic effects, potential for toxicity, and carry increased risks for other arrhythmias.(12-

184 14) In this vulnerable population, catheter ablation is often unattractive due to technical
185 complexity, moderate success rates and risk for complications.(12, 14) We now demonstrate
186 in a sizable population, that ivabradine is effective for treatment of focal AT in pediatric
187 patients with CHD, often when other anti-arrhythmic agents failed. Moreover, its efficacy
188 may be higher compared to pediatric patients (6/12, 50%) and adult patients with normal
189 anatomy (18/34, 64%).(5, 6)

190 *Alternative mechanisms underlying focal AT*

191 Although focal AT are from a mechanistic point of view due enhanced automaticity, it is not
192 restricted to this mechanism.(17) Micro-reentry and triggered activity may also underly focal
193 AT, which could explain the non-response in selected patients with focal AT. Various reports
194 show that these alternative mechanisms are frequent in pediatric and adult patients with
195 and without congenital heart disease.(17-19) In addition, increased automaticity – and thus
196 pacemaker activity – are not solely dependent on HCN channels, which are the electrical
197 target for ivabradine treatment. Enhanced function of other ionic channels and their
198 currents may also be responsible for spontaneous diastolic depolarizations in selected
199 patients with automatic FAT, rendering them insensitive to ivabradine.(1)

200 *Bradycardia and side effects*

201 The minimal side-effect profile of ivabradine has been a major reason for the increased
202 interest in ivabradine as an alternative anti-arrhythmic agent for focal AT.(1, 4, 6, 15) Unlike
203 traditional anti-arrhythmic agents, ivabradine has minimal effects on blood pressure and
204 inotropy. However, an important adverse effect is bradycardia.(15, 20) While there were no
205 documented episodes of bradycardia in the case-series from Xu et al., we observed
206 bradycardia in 47% of patients.(6) Interestingly, bradycardia was not just due to depressed

207 sinoatrial node pacemaker function, 2 out of 7 patients had functional bradycardia due to
208 blocked PACs. Ivabradine can also inhibit the funny current in the atrioventricular node,
209 resulting in functional bradycardia in presence of PACs.(21)

210 In pediatric patients with complex CHD, bradycardic events may be more significant as this
211 population often has diminished ventricular function. In addition, pediatric patients < 1 year
212 of age are especially dependent on chronotropic competence. Importantly, however,
213 bradycardic events in the current study were transient or responded to reducing the
214 ivabradine dosage. A recent report showed that in the case of ivabradine overdoses (0.5
215 mg/kg due to dosing error), bradycardia did not result in hemodynamic instability in a child
216 with AT. In addition, within 28 hours of discontinuation of ivabradine sinus rhythm was
217 returned.(11) Also, pediatric patients with early post-operative AT often have temporary
218 atrial or ventricular pacing wires which could ensure sufficient ventricular rate in case of
219 persisting bradycardia.

220 *Limitations*

221 Although this is the first large retrospective single center report on the use of ivabradine in
222 pediatric with CHD, there are several limitations inherent to its design. Due to its
223 retrospective nature, there was no standardized protocol in initiation of ivabradine, resulting
224 in first, second and third-line therapy regimens in combination with various other anti-
225 arrhythmic agents. Future studies need to assess the efficacy and safety of monotherapy
226 separately from interaction with specific other anti-arrhythmic agents. Due to the relatively
227 small sample size, the study was unable to identify predictors for response, adverse events
228 and determine the optimal dose for treatment.

229 **Conclusion**

230 In infants and children with CHD, ivabradine showed a high efficacy for the treatment of
231 focal AT without any major complications. Bradycardia is a frequent adverse event; although
232 transient and short-lived, these events may require close monitoring especially in the post-
233 operative course.

234 **Funding**

235 Nawin Ramdat Misier is supported by a training grant from the Royal Netherlands Academy
236 of Arts and Sciences (KNAW)

237 References

- 238 1. Marciszek M, Paterek A, Oknińska M, Zambrowska Z, Mackiewicz U, Mączewski M.
239 Effect of ivabradine on cardiac arrhythmias: Antiarrhythmic or proarrhythmic? *Heart*
240 *Rhythm*. 2021;18(7):1230-8.
- 241 2. Cappato R, Castelvechio S, Ricci C, Bianco E, Vitali-Serdoz L, Gneccchi-Ruscione T, et al.
242 Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective,
243 randomized, placebo-controlled, double-blind, crossover evaluation. *J Am Coll Cardiol*.
244 2012;60(15):1323-9.
- 245 3. Ptaszynski P, Kaczmarek K, Ruta J, Kligenheben T, Wranicz JK. Metoprolol succinate
246 vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive
247 to previous pharmacological therapy. *Europace*. 2013;15(1):116-21.
- 248 4. Arvind B, Kothari SS, Juneja R, Saxena A, Ramakrishnan S, Gupta SK, et al. Ivabradine
249 Versus Amiodarone in the Management of Postoperative Junctional Ectopic Tachycardia: A
250 Randomized, Open-Label, Noninferiority Study. *JACC Clin Electrophysiol*. 2021;7(8):1052-60.
- 251 5. Banavalikar B, Shenthar J, Padmanabhan D, Valappil SP, Singha SI, Kottayan A, et al.
252 Clinical and Electrophysiological Correlates of Incessant Ivabradine-Sensitive Atrial
253 Tachycardia. *Circ Arrhythm Electrophysiol*. 2019;12(8):e007387.
- 254 6. Xu X, Guo Y, Gao W, Huang M, Liu T, Li F. Ivabradine monotherapy in pediatric
255 patients with focal atrial tachycardia: a single-center study. *Eur J Pediatr*. 2023;182(5):2265-
256 71.
- 257 7. Janson CM, Tan RB, Iyer VR, Vogel RL, Vetter VL, Shah MJ. Ivabradine for treatment of
258 tachyarrhythmias in children and young adults. *HeartRhythm Case Rep*. 2019;5(6):333-7.
- 259 8. Michel H, Heißenhuber F, Wellmann S, Melter M, Gerling S. Ectopic Atrial Tachycardia
260 in a 12-Month-Old Girl Treated With Ivabradine and Beta-Blocker, a Case Report. *Front*
261 *Pediatr*. 2020;8:313.
- 262 9. Hackett G, Lin TK, Imundo JR. Use of ivabradine in a critically ill pediatric patient with
263 recalcitrant ectopic atrial tachycardia and complex congenital heart disease. *HeartRhythm*
264 *Case Rep*. 2022;8(6):415-9.
- 265 10. Cohen MI, Cohen JA, Shope C, Stollar L, Collazo L. Ivabradine as a stabilising anti-
266 arrhythmic agent for multifocal atrial tachycardia. *Cardiol Young*. 2020;30(6):899-902.
- 267 11. Doctor P, Scott WA, Tindel K, Nguyen HH. Ivabradine Overdose in a Newborn:
268 Precautions of Dispensing in Infants. *Cardiol Res*. 2022;13(4):242-5.
- 269 12. Salerno JC, Kertesz NJ, Friedman RA, Fenrich AL, Jr. Clinical course of atrial ectopic
270 tachycardia is age-dependent: results and treatment in children < 3 or > =3 years of age. *J*
271 *Am Coll Cardiol*. 2004;43(3):438-44.
- 272 13. Shamszad P, Cabrera AG, Kim JJ, Moffett BS, Graves DE, Heinle JS, et al. Perioperative
273 atrial tachycardia is associated with increased mortality in infants undergoing cardiac
274 surgery. *J Thorac Cardiovasc Surg*. 2012;144(2):396-401.
- 275 14. Kang KT, Etheridge SP, Kantoch MJ, Tisma-Dupanovic S, Bradley DJ, Balaji S, et al.
276 Current management of focal atrial tachycardia in children: a multicenter experience. *Circ*
277 *Arrhythm Electrophysiol*. 2014;7(4):664-70.
- 278 15. Bonnet D, Berger F, Jokinen E, Kantor PF, Daubeney PEF. Ivabradine in Children With
279 Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. *J Am Coll Cardiol*.
280 2017;70(10):1262-72.
- 281 16. Ho J, Tumkaya T, Aryal S, Choi H, Claridge-Chang A. Moving beyond P values: data
282 analysis with estimation graphics. *Nat Methods*. 2019;16(7):565-6.

- 283 17. Liu CF, Cheung JW, Ip JE, Thomas G, Yang H, Sharma S, et al. Unifying Algorithm for
284 Mechanistic Diagnosis of Atrial Tachycardia. *Circ Arrhythm Electrophysiol.* 2016;9(8).
- 285 18. de Groot NM, Zeppenfeld K, Wijffels MC, Chan WK, Blom NA, Van der Wall EE, et al.
286 Ablation of focal atrial arrhythmia in patients with congenital heart defects after surgery:
287 role of circumscribed areas with heterogeneous conduction. *Heart Rhythm.* 2006;3(5):526-
288 35.
- 289 19. Drogalis-Kim DE, Gallotti RG, Blais BA, Perens G, Moore JP. Clinical and
290 electrophysiological properties of atrial tachycardia after pediatric heart transplantation.
291 *Pacing Clin Electrophysiol.* 2018;41(9):1093-100.
- 292 20. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, et al. Ivabradine in stable
293 coronary artery disease without clinical heart failure. *N Engl J Med.* 2014;371(12):1091-9.
- 294 21. Fontenla A, Tamargo J, Salgado R, López-Gil M, Mejía E, Matía R, et al. Ivabradine for
295 controlling heart rate in permanent atrial fibrillation: A translational clinical trial. *Heart*
296 *Rhythm.* 2023;20(6):822-30.
297
- 298

299 **Table 1**

	Study population (n=15)
Baseline characteristics	
Age (months)	7 [1-18]
Weight (kg)	6.7 [3.9-8.5]
Gender (kg)	9/15 (60%)
Complex congenital heart disease	12/15 (80%)
Diminished systolic ventricular function	4/15 (27%)
Medication characteristic	
Therapy indication:	
First line	4/15 (27%)
Second line	6/15 (40%)
Third line	1/15 (7%)
Breakthrough	4/15 (27%)
Maximum ivabradine dose (mg/kg/dose)	0.07 [0.05-0.10]
Monotherapy	2/15 (13%)
Concurrent anti-arrhythmic medications:	
Flecainide	4/15 (27%)
Amiodarone	4/15 (27%)
Beta-blocker	4/15 (27%)
Digoxin	3/15 (20%)
Dexmedetomidine	2/15 (13%)
Outcomes	

Acute success	12/15 (80%)
Adverse events:	7/15 (33%)
Sinus bradycardia	5/15 (33%)
Functional bradycardia	2/15 (13%)

300

301